SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-21-019544
Filing Date
2021-08-12
Accepted
2021-08-12 08:09:49
Documents
16
Period of Report
2021-08-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 mbrx-20210812.htm   iXBRL 8-K 22853
2 ex_269919.htm EX-99.1 78949
7 mbrx20210730_8kimg001.jpg GRAPHIC 3787
8 moleculinlogoresizedclear.jpg GRAPHIC 19339
  Complete submission text file 0001437749-21-019544.txt   284734

Data Files

Seq Description Document Type Size
3 mbrx-20210812.xsd EX-101.SCH 3594
4 mbrx-20210812_def.xml EX-101.DEF 11805
5 mbrx-20210812_lab.xml EX-101.LAB 15849
6 mbrx-20210812_pre.xml EX-101.PRE 12020
9 EXTRACTED XBRL INSTANCE DOCUMENT mbrx-20210812_htm.xml XML 2639
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

IRS No.: 474671999 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37758 | Film No.: 211165554
SIC: 2834 Pharmaceutical Preparations